Snake venom toxins from Naja nigricollis (N. nigricollis toxins)

Snake venom toxins from Naja nigricollis, the black-necked spitting cobra, comprise a complex mixture of proteins that primarily induce severe local tissue destruction and inflammation [1]. The most abundant components are three-finger toxins (3FTxs), specifically cytotoxins (cardiotoxins), which act by forming pores in cell membranes and causing rapid cytolysis [1][5]. Phospholipase A2 (PLA2) enzymes are also prevalent, contributing to both direct tissue damage and the amplification of the inflammatory response through the arachidonic acid pathway [3]. While Naja nigricollis venom contains neurotoxins, its clinical profile is dominated by dermonecrosis and swelling rather than the systemic paralysis typical of other cobras [2][5]. In a therapeutic context, these toxins are the primary targets for antivenom therapy, which utilizes purified antibodies to neutralize the venom's pathological effects [2]. Recent pharmacological research has focused on small molecule inhibitors, such as Varespladib for PLA2, to provide more rapid and tissue-penetrating neutralization than traditional antivenoms [3][4].

Other names

Black-necked spitting cobra venom proteinsNaja nigricollis cytotoxinsNaja nigricollis phospholipasesSpitting cobra venom

Antivenoms consist of polyclonal antibodies that bind to and sequester venom proteins, preventing their interaction with host cell membranes and receptors [1][2]. Small molecule inhibitors like Varespladib target the enzymatic active site of Phospholipase A2 (PLA2) to prevent phospholipid hydrolysis and the subsequent release of inflammatory mediators [3]. Metalloproteinase inhibitors like Batimastat bind to the zinc-dependent catalytic site of snake venom metalloproteinases (SVMPs) to inhibit tissue degradation and hemorrhage [4].